The Filing Desk

Amphstar Pharmaceuticals vs Ultragenyx Pharmaceutical

Amphstar Pharmaceuticals AMPH · Ultragenyx Pharmaceutical RARE · Pharmaceuticals

Amphstar Pharmaceuticals reported revenue of $720 million in fiscal 2025, about the same as Ultragenyx Pharmaceutical's $673 million in fiscal 2025. Amphstar Pharmaceuticals' revenue fell 1.6% in its latest year, and Ultragenyx Pharmaceutical's grew 20.2%. Amphstar Pharmaceuticals had an operating margin of 19.5%, against -79.5% at Ultragenyx Pharmaceutical. Free cash flow was $121 million at Amphstar Pharmaceuticals and −$472 million at Ultragenyx Pharmaceutical.

Side by side

Amphstar PharmaceuticalsUltragenyx Pharmaceutical
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$720M$673M
Revenue growth−1.6%20.2%
Revenue growth a year, last 5 years15.5%20.0%
Gross margin49.5%—
Operating margin19.5%−79.5%
Net margin13.6%−85.4%
Free cash flow$121M−$472M
Free cash flow margin16.8%−70.1%
Return on capital9.9%—
Net debt to EBITDA1.7x—
Dividends and buybacks$76M$0M
Change in diluted share count−7.4%8.9%
Last close$29.37$16.08
P/E at the last close13.4×—
Insider trades, last 12 monthssold $2.1 millionsold $3.7 million
Piotroski F-score6 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Amphstar PharmaceuticalsUltragenyx Pharmaceutical
Operating margin
Percent of revenue
Amphstar PharmaceuticalsUltragenyx Pharmaceutical
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Amphstar PharmaceuticalsUltragenyx Pharmaceutical

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Amphstar Pharmaceuticals and Ultragenyx Pharmaceutical pages.